Metformin and dapagliflozin effect on growth factor in men with type 2 diabetes and fatty liver
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests whether adding dapagliflozin to metformin affects a hormone called IGF-1, which is linked to growth and metabolism. It may help men with type 2 diabetes and fatty liver disease understand if this combination can improve their condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Men aged 30 to 60 years old
- Have type 2 diabetes with an HbA1c (average blood sugar) between 7.0% and 10.0%
- Taking metformin (1500 mg or more daily) for at least 8 weeks
- Have fatty liver disease, confirmed by a special liver scan (CAP value of 248 or higher)
- Have not used certain diabetes drugs (SGLT2 inhibitors, sulfonylureas, insulin, or GLP-1 agonists) before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine (HM11260C) to see if it helps people with type 2 diabetes who are already taking metformin and dapagliflozin but still have high blood sugar. If you qualify, it could give you a new option to better control your diabetes.
This study tests how a type of diabetes medicine called SGLT2 inhibitors affects how the liver makes sugar. It may help researchers better understand how to manage blood sugar in people with type 2 diabetes.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This study tests whether a medication called henagliflozin can help reduce liver scarring (fibrosis) in people who have both fatty liver disease (MASLD) and type 2 diabetes. It is for those whose liver stiffness and blood sugar levels are in a certain range.
This trial compares two medications, dapagliflozin and empagliflozin, to see which works better and is safer for people with type 2 diabetes and a high body mass index (BMI). If you are an adult with type 2 diabetes and a BMI of 23 or higher, this study might help find a treatment that also supports weight loss.
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.